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New RAS-Mutant Pancreatic Adenocarcinoma
With Combined BRAF and MEK Inhibition for
Metastatic Melanoma
Introduction
Combined BRAF and MEK inhibition improves the response
rate (RR) and progression-free survival for patients with V600
BRAF-mutant metastatic melanoma over single-agent BRAF inhi-
bition, with the advantage of causing fewer cutaneous squamous
cell carcinomas (cuSCCs).1 In addition to the superior efficacy,
the decrease in oncogenic toxicities favor its use over single-
agent BRAF inhibitors in both metastatic and adjuvant patients,
particularly with recent case reports of propagation of pre-
existing RAS-mutant leukemia,2 gastric and colonic polyps,3
and the possible increased risk of new BRAF wild-type primary
cutaneous melanomas4 with single-agent BRAF inhibitors.
Herein, we report the first case of a new KRAS-mutant adeno-
carcinoma diagnosed in a patient while treated with the combina-
tion of dabrafenib and trametinib for V600 BRAF–mutantmetastatic
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melanoma that was not present before initiation of the combined
BRAF andMEK inhibition.
Case Report
Awell 63-year-old man with recently diagnosedmetastatic mel-
anoma of the liver and bone presented for an opinion regarding
systemic therapy in October 2011. He had no risk factors for the
development of pancreatic cancer; hehadno family history of pancre-
atic cancer, was a life-long nonsmoker with no history of excessive
alcohol consumption at baseline and had no history of pancreatitis. A
left upper abdomen primary cutaneous melanoma was resected in
2007 (superficial spreading subtype, Breslow thickness 0.6mm, Clark
level III invasion with no ulceration, and no dermal mitoses identi-
fied). Four years later, in July 2011, he developed left axillary lymph-
adenopathy, confirmed to be melanoma on excision biopsy.
Pathology of the cleared axilla showed a further involved lymphnode,
thus a total of two of 24 lymph nodes were involved, both with
extranodal spread. The tumor cells stained positive for S100 and
negative for melan-A and HMB45. Tumor mutation testing con-
firmed the presence of a BRAF Exon 15 V600E mutation
(c.1799_1800delinsAA: p. V600E). Positron emission tomography/
computed tomography with 18F-labeled fluorodeoxyglucose (FDG
PET/CT)showedmultiple livermetastases, skeletal involvementat the
fifth left rib andL2 and3 vertebral bodies, andno focal abnormality in
the pancreas.
The patient was enrolled in cohort D of the phase I trial
BRF113220 of dabrafenib in combination with trametinib1 in No-
vember 2011 as first-line systemic therapy. The patient was treated
with single-agent dabrafenib at a dose of 75 mg twice daily for one
cycle (28 days), and thereafter received dabrafenib 75 mg twice daily
combinedwith trametinib 2mgdaily. Thepatient tolerated treatment
with minimal toxicities. At first restaging at day 54, the patient had a
RECIST 1.15 partial response (Fig 1B). Subsequently at day 141 the
patient had a RECIST complete response by CT scan with resolution
ofall livermetastasis andsclerosisof the lytic lesionatL2(Fig1).Atday
278, a 26mmhypoattenuating lesionwas identified in the head of the
pancreas with associated biliary duct dilation on CT (Fig 1C). In
retrospect this pancreatic lesionwas present onCTat day 173, but not
earlier (Fig 1, dashed red line). At day 307, he developed obstructive
jaundice, whichwas relieved by endoscopic retrograde cholangiopan-
creatography and stenting (Fig 1D). At day 355, a further FDG
PET/CT was performed revealing FDG-avid lesions within the ante-
rior portion of the pancreatic body, the uncinate process, and celiac
and precaval lymph nodes (Fig 2D, note physiological renal uptake).
These were not present on the pretreatment PET/CT (Fig 2C) and
full-dose CT scan (Fig 1A). The previously FDG-avidmelanoma liver
and skeletal metastasis at baseline (Fig 2A) were no longer visible (Fig
2B). Cytologic analysis of material obtained from an endoscopic
ultrasound-guided biopsy confirmed adenocarcinoma and the
combined dabrafenib and trametinib were ceased on day 365,
October 2012. Cancer antigen (CA) 19.9 was elevated to 1,893
U/mL (normal range, 0-34 U/mL). In retrospect, the liver metas-
tases diagnosed at the time of the left axillarymelanoma recurrence
were not considered to be pancreatic adenocarcinoma metastases
because of their complete response to BRAF/MEK inhibition, and
the lack of a pancreatic lesion on initial imaging.
InNovember 2012, a laparotomywas performed for aWhipple’s
procedure, butwas abandonedasmalignancywas encircling the celiac
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trunk. A further biopsy via endoscopic ultrasoundwas performed for
histological andmolecularanalysis.The tumorwasconfirmedtobean
adenocarcinoma with well-formed glandular arrangements (Fig 3A).
The tumor cells stained for cytokeratin (Fig 3B), andwere negative for
S100 (Fig 3C). In contrast the patients axillarymelanomahad a differ-
ing histological appearance (Fig 3D), stained negative for cytokeratin
and displayed positive for S100 (Fig 3E) and SOX-10 (Fig 3F). Subse-
quently deep amplicon-based sequencing was performed on the bi-
opsy sample using the TruSEQAmplicon Cancer panel targeting 225
loci across 48 knowncancer genes to a depthof greater than 4,000 fold
(Illumina, San Diego, CA).6 The assay identified eight missense vari-
ants (Table 1) includingKRAS (G12D) andERRB4 (R103C),while no
variants were detected in either BRAF or CDKN2A. The KRASmuta-
tionwas confirmedusing polymerase chain reaction and Sequenom
Massarray mass spectrometer (Sequenom, San Diego, CA). The
patient was screened for germline mutations in CDKN2A, as he had
developed both melanoma and pancreatic cancer, and none
were identified.
The patient was subsequently treated with gemcitabine and
nanoparticle albumin-bound paclitaxel (Abraxane) with a rapid ini-
tial improvement in CA19.9 to 262 U/mL after two cycles of therapy.
However, after the third cycle therewas a rise of CA19.9 to 774U/mL.
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Table 1. Missense Variants Identified
Gene
NCBI Reference
Sequence
Codon
Change
Protein
Substitution
Nonref Allele
Frequency (%)
Reported on
COSMIC dbSNP ID†
Minor Allele
Frequency†
ERBB4 NM_005235 CGC to TGC R103C 12.00 Yes — —
KIT NM_001093772 ATG to CTG M537L 57.00 Yes rs3822214 0.064
RET NM_020630 TAT to TTT Y791F 42.00 Yes rs77724903 N/A
KRAS NM_033360 GGT to GAT G12D 50.00 Yes — —
TP53 NM_001126116 CGC to TGC R151C 25.00 No — —
TP53 NM_001126116 GCC to CCC A27P 48.00 Yes — —
TP53 NM_001126113 CCG to CGC P72R 99.00 No rs1042522 0.398
STK11 NM_000455 TTC to TTG F354L 59.00 Yes rs59912467 0.013
Abbreviations: COSMIC, Catalogue of Somatic Mutations in Cancer; NCBI, National Center for Biotechnology Information; Nonref, nonreference.
http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/.
†http://www.ncbi.nlm.nih.gov/projects/SNP/.
Carlino et al
e54 © 2014 by American Society of Clinical Oncology JOURNAL OF CLINICAL ONCOLOGY
Downloaded from ascopubs.org by University of Queensland on January 30, 2017 from 130.102.082.157
Copyright © 2017 American Society of Clinical Oncology. All rights reserved.
A CT scan demonstrated a significant increase in the size of the
pancreatic primary and the development of two new small liver me-
tastases. Second-line chemotherapywas commencedwithoxaliplatin,
fluorouracil, and folinic acid.
Discussion
Targeting the mitogen-activated protein kinase pathway (MAPK)
pathway has revolutionized the treatment of BRAF-mutant meta-
static melanoma. Both single-agent BRAF and MEK inhibitors
improve survival compared with chemotherapy,7,8 however 4% to
31% of patients treated with type I BRAF inhibitors develop well-
differentiated cuSCCs and keratoacanthomas.9 These lesions develop
early after the commencement of vemurafenib or dabrafenib and are
due to the paradoxical activation of MAPK signaling in the setting of
upstream activation of the pathway (eg, HRAS mutations).10-13 Al-
though these cuSCCs are easilymanaged andnone havemetastasized,
their development highlights the possible risk of other malignancies
withgreatermetastaticpotential.There alsoappears tobean increased
frequency in the development of new BRAF wild-type primary cuta-
neousmelanomas in patients treated with BRAF inhibitors.4,14 A case
hasbeen reportedof acceleratedprogressionofRAS-mutant leukemia
after commencement of vemurafenib.2 The rapid progression of a
pre-existing pancreatic adenocarcinoma was reported recently in a
patient treated with vemurafenib who had a family history of both
melanoma andpancreatic adenocarcinoma, andwas known to have a
germline CDKN2Amutation.15 The development of thesemalignan-
cies soon after the initiation of BRAF inhibitor therapy suggests BRAF
inhibitors potentiate the proliferation of a pre-existing malignancy
rather than causing new malignancies. RAS wild-type gastric and
colonic polyps have been reported to occur after prolonged therapy
with vemurafenib, however nomutations in theMAPKpathwaywere
identified, andmost harbored mutations the APC gene or -catenin.
The mechanism of tumor development in these cases remains to
be elucidated.3
Paradoxical MAPK pathway activation and the associated
cuSCCs do not occur with single-agent trametinib treatment which
inhibits wild-type MEK, the kinase downstream from the RAF ki-
nases.16 CombinedBRAF (dabrafenib) andMEK(trametinib) inhibi-
tion improves the response rate and progression-free survival of
patients with V600 BRAF mutant metastatic melanoma compared
with BRAF inhibition alone with the added benefit of a reduced
incidence of cuSCCs.1 Despite this, propagation of a KRAS-mutant
colon cancer by combined dabrafenib and trametinibwas reported in
a patient with metastatic melanoma and a history of resected Dukes
stage B colonic adenocarcinoma.17 The patient’s serum carcinoem-
bryonic antigen and symptoms due to the colonic metastases im-
proved with treatment with single-agent trametinib, suggesting that
BRAF inhibition was driving proliferation.17 This case of colorectal
cancer differs from our case of de novo pancreatic cancer, as it was a
recurrenceofapre-existingmalignancy. Inretrospect thecoloncancer
was present as a malignant pleural effusion before initiating therapy
with dabrafenib/trametinib.
Given the strong evidence for paradoxical activation of the
MAPK pathway by BRAF inhibitors, the case described herein illus-
trates there is a risk of development or progression ofmalignancies of
significant metastatic potential with BRAF inhibitor treatment, and
the risk may not be completely negated by the addition of a MEK
inhibitor. The pancreatic adenocarcinoma in this case was not clini-
cally apparent by CT or PET scan before commencing treatment for
metastatic melanoma and progressed to become locally advanced.
Pre-existing microscopic disease may have been present that was
propagated by BRAF inhibitor therapy but may have eventually
developed irrespective of inhibitor therapy. Historically, this risk is
of minimal clinical consequence given the poor prognosis of pa-
tientswithmetastaticmelanoma.18Withmore effective systemic ther-
apies, the risk has greater significance, particularly in patients such as
this who have a complete response to therapy. Ofmore concern is the
potential formalignancies todevelop inpatients treatedwith adjuvant
MAPK inhibitors.
Lastly, this casehighlights theneed tobiopsyanynewradiological
lesion that develops during BRAF inhibitor therapy, whether single
agent or combined with other drugs, given the risk of a new or prop-
agating malignancy. This is particularly important in patients whose
pre-existing melanoma remains stable or is responding well.
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